Jumping genes which can lead to rare syndrome in children identified
A new family of DNA elements which control the activation of certain genes to cause a rare disease known as 'MSL3 syndrome’ in children has been identified.
Lead author Dr Pradeepa Madapura with the research team
The study led by researchers at the Queen Mary University of London and published in Nature Structural & Molecular Biology shines a new light on the mechanism behind this poorly understood disease, hoping that it can lead to better treatments for this and similar diseases in the future.
Mutations in the MSL3 gene are known to cause a rare disease in children called MSL3 syndrome - a newly discovered disease with only around 50 registered diagnoses worldwide, although scientists predict that more cases are currently undiagnosed.
MLS3 syndrome is a disease that is poorly understood. The mechanism by which MSL3 mutations lead to this syndrome is not known. There is only one previous study which discovered this disease gene, but it is not clear why mutations in MSL3 cause this disorder.
Epigenetics is the study of observable changes of an individual resulting from the interaction of its genotype with the environment: changes that do not involve alterations in the DNA sequence. In this study, researchers discovered that a family of mobile DNA known as ‘LINE1 elements’ could function as a switch to turn on certain genes. Previously, researchers thought that the MSL3 complex regulates genes directly. This research shows that the MSL3 complex regulates genes by activating these mobile DNA elements.
Mutations in the MSL3 gene can lead to disturbing genes involved in development. The developmental genes are intact, but the programme that determines how the genetic information will be fine-tuned is impaired. This could lead to a global delay in the development of multiple organs, including the brain.
This research was funded by the UK Research and Innovation Medical Research Council (MRC) and Barts Charity and led by Dr Pradeepa Madapura and his team of postdoctoral researchers, Dr Debosree Pal and Dr Manthan Patel from Queen Mary University of London, and collaborators from the Wellcome-MRC Cambridge Stem Cell Institute at the University of Cambridge and the Francis Crick Institute.
“Although these DNA elements are popularly known as jumping genes, most are immobile and not harmful. We only know the tip of the iceberg about how host species are using this virus-like DNA to our own advantage,” says lead author Dr Pradeepa Madapura.
Although this work provides novel insights into how MSL functions to regulate our genome, further research is needed to test whether drugs that alter this epigenetic pathway alleviate symptoms in children with mutations in their MSL genes. However, many epigenetic drugs that target this pathway are already in clinical trials for cancer therapy.